Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Web: http://genomediscovery.org
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, Molecular therapy for Metabolic disorders: Tumor suppressor ING1b decreases insulin sensitivity, mucosal immunity and increases endotoxaemia via down regulation of Interleukin-22, 28/October/2014, 22.32, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org
Courtesy: When you cite drop us a line at info@genomediscovery.org
* Research cooperation
Undisclosed information: An insight into how ING1b decreases insulin sensitivity, mucosal immunity and increases endotoxaemia.
Significance: This study suggests, for the first time, that ING1b, by decreasing the expression of IL-22, it may decrease insulin sensitivity, gut immunity; and increase endotoxaemia. Together, this study suggests that pharmacological formulations encompassing “ING1b inhibitors“ may be used to treat metabolic disorders, including T2DM and cardiac diseases.
